Literature DB >> 10595909

Estrogen receptor-positive proliferating cells in the normal and precancerous breast.

B S Shoker1, C Jarvis, R B Clarke, E Anderson, J Hewlett, M P Davies, D R Sibson, J P Sloane.   

Abstract

Recently it has been shown that epithelial cell expression of the estrogen receptor (ER) and that of the proliferation-associated marker Ki-67 are almost mutually exclusive in the normal premenopausal human breast but that coexpression frequently occurs in estrogen receptor-positive (ER+) breast cancers. This coexpression may indicate disordered expression of ER in the cell cycle or failure to suppress division of ER+ cells and could be important in neoplastic transformation. The purpose of this study was to determine whether in situ proliferations known to be associated with different levels of risk for developing breast cancer contain these coexpressing cells and, if so, the stage at which they occur. We found that ER+ proliferating cells were rare in premenopausal lobules but increased with age in the normal breast. There was no difference in nonlesional tissue between cancerous and noncancerous breasts. The percentage of dual-expressing cells was significantly increased, however, in all of the in situ proliferations and correlated positively with the level of risk of developing breast cancer. We suggest that development of at least some human breast cancers is associated with increasing failure to down-regulate ER as cells enter the cycle or to suppress division of ER+ cells. The mechanism may involve the loss of a tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595909      PMCID: PMC1866935          DOI: 10.1016/S0002-9440(10)65498-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  17 in total

1.  Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia.

Authors:  D L Page; L W Rogers
Journal:  Hum Pathol       Date:  1992-10       Impact factor: 3.466

2.  Is tamoxifen effective in prevention of breast cancer?

Authors:  K I Pritchard
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

3.  Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.

Authors:  H Buerger; F Otterbach; R Simon; C Poremba; R Diallo; T Decker; L Riethdorf; C Brinkschmidt; B Dockhorn-Dworniczak; W Boecker
Journal:  J Pathol       Date:  1999-03       Impact factor: 7.996

Review 4.  Reproductive factors and breast cancer.

Authors:  J L Kelsey; M D Gammon; E M John
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

5.  Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations.

Authors:  S R Lakhani; D N Slack; R A Hamoudi; N Collins; M R Stratton; J P Sloane
Journal:  Lab Invest       Date:  1996-01       Impact factor: 5.662

6.  Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast.

Authors:  G Williams; E Anderson; A Howell; R Watson; J Coyne; S A Roberts; C S Potten
Journal:  Int J Cancer       Date:  1991-05-10       Impact factor: 7.396

7.  Oestrogen receptor expression in the normal and pre-cancerous breast.

Authors:  B S Shoker; C Jarvis; D R Sibson; C Walker; J P Sloane
Journal:  J Pathol       Date:  1999-07       Impact factor: 7.996

8.  Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen.

Authors:  S R Johnston; K A MacLennan; N P Sacks; J Salter; I E Smith; M Dowsett
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

9.  The novel estrogen-responsive B-box protein (EBBP) gene is tamoxifen-regulated in cells expressing an estrogen receptor DNA-binding domain mutant.

Authors:  H L Liu; E Golder-Novoselsky; M H Seto; L Webster; J McClary; D A Zajchowski
Journal:  Mol Endocrinol       Date:  1998-11

10.  Risk factors for breast cancer in women with proliferative breast disease.

Authors:  W D Dupont; D L Page
Journal:  N Engl J Med       Date:  1985-01-17       Impact factor: 91.245

View more
  87 in total

1.  Distinct expression patterns of ER alpha and ER beta in normal human mammary gland.

Authors:  V Speirs; G P Skliris; S E Burdall; P J Carder
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

2.  Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland.

Authors:  Guojun Cheng; Zhang Weihua; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

Review 3.  Steroid receptors and cell cycle in normal mammary epithelium.

Authors:  Elizabeth Anderson; Robert B Clarke
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

4.  Reconstruction of functionally normal and malignant human breast tissues in mice.

Authors:  Charlotte Kuperwasser; Tony Chavarria; Min Wu; Greg Magrane; Joe W Gray; Loucinda Carey; Andrea Richardson; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

5.  Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status.

Authors:  Tianhong Li; Federica Sotgia; Magalis A Vuolo; Maomi Li; Wan Cai Yang; Richard G Pestell; Joseph A Sparano; Michael P Lisanti
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

6.  The Er/Ki-67 Proportion in Breast Tumours - An Immunohistochemical Study.

Authors:  M K Rai
Journal:  J Clin Diagn Res       Date:  2016-04-01

7.  Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.

Authors:  Natalija Dedić Plavetić; Jasminka Jakić-Razumović; Ana Kulić; Maja Sirotković-Skerlev; Marina Barić; Damir Vrbanec
Journal:  Pathol Oncol Res       Date:  2014-08-06       Impact factor: 3.201

8.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

9.  [Immunohistochemistry in breast pathology: differential diagnosis of epithelial breast lesions].

Authors:  W Böcker; D Hungermann; S Weigel; J Tio; T Decker
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

Review 10.  The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective.

Authors:  A Urruticoechea
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.